Back to Journals » Biologics: Targets and Therapy » Volume 13

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Total article views   HTML views PDF downloads Totals
10,185 Dovepress* 9,298+ 748 10,046
PubMed Central* 887 143 1,030
Totals 10,185 891 11,076
*Since 25 November 2019

View citations on PubMed Central and Google Scholar